ICH Members and Observers: An Overview

This blog represents:

1. What are ICH regions?
2. Purpose of ICH
3. Who are members and observers?

Introduction

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) plays an important role in developing harmonised technical guidelines for pharmaceutical development, registration, and post-approval activities.

ICH brings together regulatory authorities and the pharmaceutical industry to develop common technical standards covering areas such as quality, safety, efficacy, and multidisciplinary regulatory requirements.

Although ICH originated from cooperation among Europe, Japan, and the United States, its membership and global influence have expanded significantly over time. Today, ICH involves regulatory authorities and industry organisations from multiple regions around the world.

Purpose of ICH

ICH was established to create a platform where regulatory and pharmaceutical-industry experts could work together to harmonise technical requirements for pharmaceutical products.

The objective is to reduce unnecessary differences in regulatory requirements while maintaining appropriate standards for the quality, safety, and efficacy of medicines.

Harmonisation can help reduce duplication during pharmaceutical development and regulatory submissions and can make it easier for companies to prepare information that can be used across multiple jurisdictions.

One important example is the Common Technical Document (CTD). ICH’s CTD framework brings quality, safety, and efficacy information into a common structure. Modules 2–5 are harmonised, while Module 1 remains region-specific.

ICH Founding Members

ICH was originally established through cooperation between regulatory authorities and pharmaceutical-industry organisations from Europe, Japan, and the United States.

The founding regulatory members are:

• European Commission (EC), Europe
  
• U.S. Food and Drug Administration (FDA), United States
  
• MHLW/PMDA, Japan
  

The founding industry members are:

• European Federation of Pharmaceutical Industries and Associations (EFPIA)
  
• Japan Pharmaceutical Manufacturers Association (JPMA)
  
• Pharmaceutical Research and Manufacturers of America (PhRMA)
  

These organisations formed the foundation of the original ICH framework.

ICH Membership Categories

As ICH has expanded, its membership structure has developed beyond the original founding organisations.

ICH currently categorises Members into several groups:

1. Founding Regulatory Members

These are the original regulatory members:

• European Commission
  
• U.S. FDA
  
• MHLW/PMDA Japan
  

2. Founding Industry Members

These include:

• EFPIA
  
• JPMA
  
• PhRMA
  

3. Standing Regulatory Members

Standing Regulatory Members currently include:

• Health Canada
  
• Swissmedic, Switzerland
  

4. Regulatory Members

The current Regulatory Members include authorities from countries and regions such as:

• Argentina
  
• Brazil
  
• China
  
• Chinese Taipei
  
• Egypt
  
• Jordan
  
• Mexico
  
• Nigeria
  
• Republic of Korea
  
• Saudi Arabia
  
• Singapore
  
• South Africa
  
• Türkiye
  
• United Kingdom
  

The exact membership list can change as new members are admitted. As of November 2025, ICH listed 25 Members in total.

5. Industry Members

ICH also includes international industry organisations representing different areas of the pharmaceutical and healthcare sector.

As of November 2025, the Industry Members included:

• Biotechnology Innovation Organization (BIO)
  
• Global Self-Care Federation
  
• International Generic and Biosimilar Medicines Association (IGBA)

ICH Observers

ICH also works with organisations and authorities that participate as Observers.

Observers can contribute to the international harmonisation process and may participate in ICH activities without having the same status as Members.

The ICH Assembly has continued to expand its network of Observers. In November 2025, ICH reported 41 Observers.

Observers can include:

• Regulatory authorities
  
• International organisations
  
• Regional harmonisation initiatives
  
• Pharmaceutical-industry organisations
  
• Other organisations with an interest in ICH guidelines
  

The Observer category is particularly important because it provides a pathway for broader international participation in the harmonisation process.

Are ICH Guidelines Limited to ICH Regions?

The direct is “No”.

ICH develops harmonised guidelines through its international process, and these guidelines are subsequently implemented by participating regulatory authorities according to their applicable national, regional, or local procedures.

At Step 5 of the ICH process, an adopted harmonised guideline moves into implementation by ICH Regulatory Members and Observers within their respective jurisdictions.

This means that an ICH guideline does not automatically become a single worldwide law.

Instead, each regulatory authority determines how the guideline is implemented within its own regulatory framework.

As a result, countries that are not ICH Members may also reference or adopt ICH guidelines within their own regulatory systems.

Key Takeaways

• ICH is an international harmonisation organisation bringing together regulatory authorities and pharmaceutical-industry organisations.
  
• Europe, Japan, and the United States were the founding participants in the original ICH framework.
  
• ICH membership has expanded significantly and now includes regulatory authorities and industry organisations from many other jurisdictions.
  
• ICH has different categories of Members, including Founding Regulatory Members, Founding Industry Members, Standing Regulatory Members, Regulatory Members, and Industry Members.
  
• ICH also has a growing network of Observers.
  
• ICH guidelines cover Quality, Safety, Efficacy, and Multidisciplinary areas.
  
• ICH guidelines are implemented through the applicable regulatory procedures of participating jurisdictions.
  
• ICH guidelines are influential globally, but implementation and legal status can differ between countries.
  
• Companies should always check the applicable national or regional implementation when applying an ICH guideline to a regulatory activity.
  

Conclusion

ICH has evolved from its original cooperation among Europe, Japan, and the United States into a much broader international harmonisation framework.

Its work helps establish common technical expectations for pharmaceutical development, registration, and post-approval activities while allowing individual regulatory jurisdictions to implement those recommendations through their own regulatory systems.

For pharmaceutical and pharmacovigilance professionals, understanding ICH is therefore more than knowing its founding regions. It requires understanding how ICH is structured, who participates, how guidelines are developed and implemented, and how harmonised requirements interact with national regulatory requirements.

This distinction is particularly important when working on global clinical trials, pharmacovigilance systems, safety reporting, regulatory submissions, and post-marketing activities.